Bremelanotide · MC4R agonist · sexual desire · FDA-approved (2019) · on-demand use
The ReferenceBenefits, protocols and preparationOpen the reference →PT-141 acts on the central nervous system — not on peripheral circulation like Viagra/Cialis. That's why it works in both sexes and in cases where PDE5 inhibitors don't respond.
Activates melanocortin receptors in the hypothalamus and stimulates the central dopaminergic pathway: desire starts in the brain, not in the circulation.
It acts on the MC4R receptor in both sexes, but the evidence is not symmetrical: the FDA approval (Vyleesi, 2019) covers hypoactive sexual desire disorder (HSDD) in premenopausal women. In men the studies are older and preliminary (phase 2 in erectile dysfunction) and that route was never approved.
Unlike sildenafil (purely vascular), PT-141 also acts on the mental and emotional component of desire. Useful when the cause is psychological or mixed.
It does not change your own hormone levels. In the trials it worked the same with normal or low testosterone, and it is compatible with testosterone therapy.

Libido & desire
BioLibidoPT-141More sexual desire · Supports erection
+ BioDriveKisspeptin+ Adds: Own testosterone without shutting the axisPT-141 (bremelanotide) is a synthetic cyclic heptapeptide, an analog of α-MSH (alpha-melanocyte-stimulating hormone). It acts as an agonist of the MC4R and MC3R melanocortin receptors in the central nervous system, mainly in the hypothalamus, where it stimulates the dopaminergic pathway of sexual desire and arousal.
SuperBio Labs PT-141 is supplied as a lyophilized powder with verified HPLC purity ≥99%. Every batch ships with an independent Certificate of Analysis confirming identity by LC-MS, peptide content (98–102%), and endotoxin levels (<1.0 EU/mg).
The pharmaceutical version of PT-141 (Vyleesi®) has been FDA-approved since 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women, after two phase 3 trials with about 1,200 women. Unlike sildenafil or tadalafil, which act on blood vessels, PT-141 acts in the brain, on desire and arousal. In men there are phase 2 studies in erectile dysfunction, but that indication was never approved. It is used on demand, not daily.
Informed professional research use only.
Each order includes everything needed for your on-demand applications. No separate purchases required.
This product meets all five — your batch COA ships with the kit.
The official protocol included in the kit: on-demand use, applied about 2 hours before, with no continuous cycle.
ALWAYS start with a 0.5 mg dose to assess individual response and tolerance (especially nausea, the most common side effect). Do NOT combine with poppers, simultaneous sildenafil/tadalafil, or antihypertensive medication without medical consultation.
Hypoactive sexual desire before menopause · the FDA-approved indication.
Men for whom sildenafil or tadalafil don't work · phase 2 evidence, never approved.
When stress or anxiety weigh more than circulation · it works through the central pathway.
Low desire linked to antidepressants · works through another pathway without changing the medication · limited evidence.
Occasional use · at most 1 dose in 24 hours and 8 per month · no continuous protocol needed.
The most common side effect is nausea. In the phase 3 trials 40% of women had it (21% with the first dose); 13% needed an anti-nausea medicine and 8% stopped because of it. It usually appears within the first hour and passes in 1–2 hours. That is why it makes sense to start with a lower test dose.
Others: facial flushing · occasional headache · a temporary rise in blood pressure (about 6/3 mmHg, peaking at 2–4 hours, back to normal in about 12 hours) · darkening of freckles or moles with very frequent use (rare). Not used with uncontrolled hypertension or cardiovascular disease. It lowers the absorption of oral naltrexone. A light meal beforehand reduces nausea.
| Also known as | Bremelanotide |
| CAS number | 189691-06-3 |
| Molecular weight | 1025.16 Da |
| Sequence | Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH |
| Purity (HPLC) | ≥99% |
| Format | Lyophilized powder |
| Quantity | 5 / 10 mg per vial |
| Endotoxins | <1.0 EU/mg |
| Storage | −20 °C, protected from light |
| Clinical reference | Vyleesi® (Palatin Technologies, FDA 2019) |
| Use | Use under professional judgment |